THE PREVALENCE AND CLINICAL FEATURES OF GOUT AND CALCIUM PYROPHOSPHATE DEPOSITION DISEASE IN PATIENTS WITH ACUTE ARTHRITIS

Objective: to study the rate of gout and calcium pyrophosphate deposition disease (CPDD) and to provide their clinical characteristics in patients with acute arthritis.

Subjects and methods. The investigation enrolled 150 patients (97 men and 53 women) with acute mono- or oligoarthritis of no more than 2 weeks’ duration who had visited the Outpatient Department of V.A. Nasonova Research Institute of Rheumatology. Their mean age was 60.2±12.0 years (range, 28–76 years). All the patients underwent inflamed joint puncture and synovial fluid (SF) crystal identification by polarized microscopy using an Olympus CX31-P compensator.The diagnosis of CPDD was established in compliance with the criteria elaborated by D. McCarty. Gout was diagnosed only when sodium monourate (SMU) crystals were found in SF.

Results and discussion. The investigation revealed gout in 51 (34%) patients, CPDD in 45 (30%), coincidence of gout and CPDD in 15 (14%), and 39 (26%) patients had other diseases: 15 (10%) – osteoarthritis, 6 (4%) – rheumatoid arthritis, 5 (3%) – septic arthritis, 5 (3%) – psoriatic arthritis, 2 (1%) – ankylosing spondyloarthritis, 4 (3%) – injury, and 5 (3%) – undifferentiated spondyloarthritis. There were 40 men and 11 women among the patients with gout and 13 men and 32 women among those with CPDD. The patients with gout were younger than those with CPDD (35.5±8.9 and 58.4±12.8 years, respectively; p < 0.05). In the patients with CPDD, knee, ankle, and first metatarsophalangeal joint arthritis was present in 34 (76.3%), 17 (30.3%), and 4 (9%) cases, respectively. Arthritis developed within a few hours in 90% of the patients with gout and in 33.3% of those with CPDD (p < 0.001). Monoarthritis was significantly more common in gout whereas oligoarthritis – in CPDD (p < 0.05). Visual analog scale pain intensity averaged 78.4±12.5 mm and 54.32±22.02 mm (p < 0.05), duration of arthritis – 10.3±3.8 days and 3.4±2.1 days (p < 0.05) in gout and CPDD respectively.

Conclusion. CPDD is the most common (60%) cause of acute arthritis in women and the second most frequent (13%) cause in men (following gout). Acute arthritis develops more slowly and persists for a longer period of time in patients with CPDD than in those with gout.

1. Барскова ВГ, Мукагова МВ, Северинова МВ и др. Диагностика подагры. Сибирский медицинский журнал. 2012;(5):132–5 [Barskova VG, Mukagova MV, Severinova MV, et al. Diagnosis of gout. Sibirskii meditsinskii zhurnal. 2012;(5):132–5 (In Russ.)].

2. Taylor WJ, Fransen J, Dalbeth N, et al. Performance of classification criteria for gout in early and established disease. Ann Rheum Dis. 2014 Oct 28. pii: annrheumdis-2014-206364. doi: 10.1136/annrheumdis-2014-206364 [Epub ahead of print].

3. Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563–70. doi: 10.1136/ard.2010.139105

4. Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study.I. The MAPPING study. Clin Exp Rheumatol. 2005;23(6):819–28.

5. Barskova VG, Kudaeva FM, Bozhieva LA, et al. Comparison of three imaging techniques in diagnosis of chondrocalcinosis of the knees in calcium pyrophosphate deposition disease. Rheumatology (Oxford). 2013;52(6):1090–4. doi: 10.1093/rheumatology/kes433

6. McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease. Arthr Rheum. 1976;19 Suppl 3:275–85. doi: 10.1002/1529-0131(197605/06)19:3+<275::AID-ART1780190702>3.0.CO;2-0

7. Shmerling RH, Delbanco TL, Tosteson AN, et al. Synovial fluid tests. What should be ordered? JAMA 1990;264:1009–14. doi: 10.1001/jama.1990.03450080095039

8. Jeng GW, Wang CR, Liu ST, et al. Measurement of synovial tumor necrosis factor-alpha in diagnosing emergency patients with bacterial arthritis. Am J Emerg Med. 1997;15:626–9. doi.org/10.1016/S0735-6757(97)90173-X

9. Parker JD, Capell HA. An acute arthritis clinic — one year’s experience. Br J Rheumatol. 1986;25:293. doi: 10.1093/rheumatology/25.3.293

10. Freed JF, Nies KM, Boyer RS, et al. Acute monoarticular arthritis. A diagnostic approach. JAMA 1980;243:2314–6. doi: 10.1001/jama.1980.03300480034021

11. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301–11. doi: 10.1136/ard.2006.055251

12. Liote F, Lancrenon S, Lanz S, et al. GOSPEL: prospective survey of gout in France. Part I: design and patients characteristics (n=1003). Joint Bone Spine. 2012;79:464–70. doi: 10.1016/j.jbspin.2011.12.006

13. Louthrenoo W, Sukitawut W. Calcium pyrophosphate dihydrate crystal deposition: a clinical and laboratory analysis of 91 Thai patients. J Med Asoc Thai. 1999;82(6):569–76.

14. Кудаева ФМ, Владимиров СА, Елисеев МС и др. Особенности клинических проявлений болезни депонирования кристаллов пирофосфата кальция. Научно- практическая ревматология. 2014;52(4):405–9 [Kudaeva FM, Vladimirov SA, Eliseev MS, et al. The clinical manifestations of calcium pyrophosphate crystal deposition disease. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):405–9 (In Russ.)]. doi: 10.14412/1995-4484-2014-405-409

15. Ramonda R, Musaccino E, Perissinoto E, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. 2009;27(6):981–4.

16. Neame RL, Carr AJ, Muir K, et al. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62(6):513–8. doi: 10.1136/ard.62.6.513

17. Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the erderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989;16(9):1241–5.

18. Viriyavejkul P, Wilairatana V, Tanavalee A, et al. Comparison of characteristics of patients with and without calcium pyrophosphate dihydrate crystal deposition desease who underwent total knee replacement surgery for osteoarthritis. Osteoarthritis Cartilage. 2007;1(2):232–5. doi: 10.1016/j.joca.2006.08.012

19. Filippou G, Frediani B, Gallo A, et al. A «new» technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. Ann Rheum Dis. 2007;66(8):1126–8. doi: 10.1136/ard.2007.069344